Biomedicine & Pharmacotherapy · 2019 · 12 citations · 45 references
MedicinePharmacologyPharmacotherapyClinical PharmacologyHemostasisPharmacodynamicsAntiplatelet TherapyAntithrombotic TherapyPlatelet ActivationPlatelet AggregationPlatelet FunctionThrombosisAntiplatelet Drug MechanismsAntiplatelet DrugsArachidonic Acid SignalingCombination Antiplatelet TherapyPlatelet Aggregation InhibitionPlatelet InhibitionPlatelet Thrombus FormationThrombosis Mechanisms
) and 2.8-fold increase in suppression of AA-induced platelet aggregation in mice when compared with use of aspirin alone. In the rat thrombus formation model, vicagrel (1 mg/kg) enhanced inhibition of thrombosis formation by aspirin (5 mg/kg), but not vice versa. We conclude that vicagrel increases platelet responses to aspirin and also enhances inhibition of thrombus formation of aspirin due to decreased CES2-catalyzed aspirin inactivation in rodents, and that an integrated net effect on thrombus formation in vivo is superior to inhibition of AA- or ADP-induced platelet aggregation ex vivo by either of the two drugs if taken concomitantly.
45
Hans‐Christoph Diener, Julien Bogousslavsky, Lawrence Brass et al. · The Lancet · 2004 · 2.3K citations
Cyclooxygenase Inhibitors and the Antiplatelet Effects of Aspirin
Francesca Catella-Lawson, Muredach P. Reilly, Shiv Kapoor et al. · New England Journal of Medicine · 2001 · 1.4K citations · Full text
Man Tang, Madhu Mukundan, Jian Yang et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 250 citations